Second-generation aptamer-conjugated PSMA-targeted delivery system for prostate cancer therapy
Xin Wu1,*, Baoyue Ding1,2,*, Jing Gao3,*, Huanyun Wang4, Wei Fan1, Xiang Wang1,5, Wei Zhang1, Xiaoyu Wang1, Lihua Ye1, Min Zhang1, Xueying Ding3, Jiyong Liu1, Quangang Zhu1, Shen Gao11Department of Pharmaceutics, Changhai Hospital, Second Military Medical University, Shanghai; 2Medical College of Ji...
Guardado en:
Autores principales: | Zhu Q, Liu J, Ding X, Zhang M, Ye L, Wang X, Zhang W, Fan W, Wang H, Gao J, Ding B, Wu X, Gao S |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Dove Medical Press
2011
|
Materias: | |
Acceso en línea: | https://doaj.org/article/9594f56739a64e37a14af350f73b043d |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Diagnosis of prostate cancer using anti-PSMA aptamer A10-3.2-oriented lipid nanobubbles
por: Fan X, et al.
Publicado: (2016) -
Study on the prostate cancer-targeting mechanism of aptamer-modified nanoparticles and their potential anticancer effect in vivo
por: Wu X, et al.
Publicado: (2014) -
Targeted delivery of cytotoxic proteins to prostate cancer via conjugation to small molecule urea-based PSMA inhibitors
por: O. C. Rogers, et al.
Publicado: (2021) -
Aptamer–drug conjugate: targeted delivery of doxorubicin in a HER3 aptamer-functionalized liposomal delivery system reduces cardiotoxicity
por: Dou XQ, et al.
Publicado: (2018) -
Degradable gene delivery systems based on Pluronics-modified low-molecular-weight polyethylenimine: preparation, characterization, intracellular trafficking, and cellular distribution
por: Ding X, et al.
Publicado: (2012)